Novel CMR-imaging biomarkers to track response to treatment including Sotatercept in a patient with idiopathic pulmonary arterial hypertension: a case report

Clicks: 7
ID: 334087
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #387 of 408 articles by views in European Heart Journal - Case Reports

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 408 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Pulmonary arterial hypertension (PAH) causes progressive right ventricular (RV) pressure overload and left ventricular (LV) underfilling. Sotatercept is an activin-signal inhibitor, approved by FDA in 2024 and EMA in 2025, as an add-on treatment in adult patients with PAH. Cardiovascular magnetic resonance (CMR) derived atrioventricular plane displacement (AVPD) and left ventricular pressure-volume (PV) loops may represent non-invasive markers of treatment response, particularly important as novel therapies addressing remodelling emerge. Case summary A 30-year-old woman was diagnosed with idiopathic PAH (IPAH), after presenting with dyspnoea and peripheral oedema. Baseline CMR showed severe RV dilation, reduced RV ejection fraction, and low indexed LV stroke volume, with reduced bilateral AVPD and markedly impaired LV PV-loop indices, with low stroke work, low mean external power, and high ventriculo-arterial coupling. Initial dual PAH therapy, with an endothelin receptor antagonist (ERA) and a phosphodiesterase five inhibitor (PDE5i) initially improved symptoms, pulmonary vascular resistance, as well as AVPD and PV-loop derived indices, whereas conventional CMR indices showed only minimal change. One year later, despite triple therapy, including prostacyclin analogue, the patient deteriorated clinically and CMR showed worsening of AVPD and PV-loop indices. Treatment escalation with Sotatercept immediately improved clinical status, haemodynamic, AVPD, and PV-loop indices despite persistent RV remodelling. Discussion Serial CMR-derived AVPD and LV PV-loops may provide clinically useful additional information during longitudinal follow-up of PAH patients, especially in those approaching maximal available medical therapies. In the present case, both AVPD and LV PV-loops reflected treatment response, and showed significant improvement after initiation of Sotatercept.
Reference Key
openalex_W7223682344 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Alessandro Castiglione, Barbro Kjellström, Göran Rådegran, Ellen Ostenfeld
Are you one of these authors? Claim your profile
Journal European Heart Journal - Case Reports
Year 2026
DOI
10.1093/ehjcr/ytag763
URL
https://academic.oup.com/ehjcr/advance-article-pdf/doi/10.1093/ehjcr/ytag763/72517105/ytag763.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.